anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although various treatment methods and drugs have been developed for pollinosis, because pollinosis symptoms are considered to be pathological physiological effects and are with those methods and drugs, a method or a drug that completely cures pollinosis has not been found. With the existing treatment methods and drugs, there are various problems such as concerns about costs, the required amount of time, and side effects, and it is not possible to achieve a complete cure. The present application addresses the problem of completely curing pollinosis. As a drug, edible salt and an organic acid at pH 3 are used. The drug is repeatedly introduced three times into the nasal cavity; the drug introduction into the nasal cavity is repeated three more times on a later date; and the drug introduction into the nasal cavity is additionally repeated on a later date. By doing so, antibodies or the like in mucus layers in the nasal cavity and cells or the like related to the pollinosis development are eliminated by causing necrosis thereof or by being washed away to outside the body, and the production of new antibodies is suppressed or halted.
Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
Selenium (Se) is involved in many physiopathologic processes in humans and animals and is strongly associated with the development of heart disease. Lipopolysaccharides (LPS) are cell wall components of gram-negative bacteria that are present in large quantities during environmental pollution. To investigate the mechanism of LPS-induced cardiac injury and the efficacy of the therapeutic effect of SeMet on LPS, a chicken model supplemented with selenomethionine (SeMet) and/or LPS treatment, as well as a primary chicken embryo cardiomyocyte model with the combined effect of SeMet / JAK2 inhibitor (INCB018424) and/or LPS were established in this experiment. CCK8 kit, Trypan blue staining, DCFH-DA staining, oxidative stress kits, immunofluorescence staining, LDH kit, real-time fluorescence quantitative PCR, and western blot were used. The results proved that LPS exposure led to ROS explosion, hindered the antioxidant system, promoted the expression of the JAK2 pathway, and increased the expression of genes involved in the pyroptosis pathway, inflammatory factors, and heat shock proteins (HSPs). Upon co-treatment with SeMet and LPS, SeMet reduced LPS-induced pyroptosis and inflammation and restored the expression of HSPs by inhibiting the ROS burst and modulating the antioxidant capacity. Co-treatment with INCB018424 and LPS resulted in inhibited of the JAK2 pathway, attenuating pyroptosis, inflammation, and high expression of HSPs. Thus, LPS induced pyroptosis, inflammation, and changes in HSPs activity by activating of the JAK2 / STAT3 / A20 signaling axis in chicken hearts. Moreover, SeMet has a positive effect on LPS-induced injury. This work further provides a theoretical basis for treating cardiac injury by SeMet.
Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
Small cell lung cancer (SCLC) is the most aggressive lung cancer entity with an extremely limited therapeutic outcome. Most patients are diagnosed at an extensive stage. However, the molecular mechanisms driving SCLC invasion and metastasis remain largely elusive. We used an autochthonous SCLC mouse model and matched samples from patients with primary and metastatic SCLC to investigate the molecular characteristics of tumor metastasis. We demonstrate that tumor cell invasion and liver metastasis in SCLC are triggered by an Angiopoietin-2 (ANG-2)/Integrin β-1-dependent pathway in tumor cells, mediated by focal adhesion kinase/Src kinase signaling. Strikingly, CRISPR-Cas9 KO of Integrin β-1 or blocking Integrin β-1 signaling by an anti-ANG-2 treatment abrogates liver metastasis formation in vivo. Interestingly, analysis of a unique collection of matched samples from patients with primary and metastatic SCLC confirmed a strong increase of Integrin β-1 in liver metastasis in comparison with the primary tumor. We further show that ANG-2 blockade combined with PD-1-targeted by anti-PD-1 treatment displays synergistic treatment effects in SCLC. Together, our data demonstrate a fundamental role of ANG-2/Integrin β-1 signaling in SCLC cells for tumor cell invasion and liver metastasis and provide a potentially new effective treatment strategy for patients with SCLC.
The invention relates to a dahurican patrinia tablet and a manufacturing method thereof, which is the rootstalk of Patrinia scabiosaefolia Fisch.ex Trev. that is a valerianaceae plant and an extract tablet of a root. An extract and auxiliary materials are pressed into the tablet and coated with a film. The manufacturing method is as follows: raw medicine materials are grinded; then the raw medicine materials are moistened, soaked and percolated by ethanol until color gets light; percolation solution is concentrated to obtain the extract; the extract is dried and grinded into extract powder; starch is proportionally added and mixed with the extract powder evenly; the starch and the extract powder undergo the processes of damp granulation, drying and finishing; magnesium stearate is added and mixed together; and the extract powder, the starch and the magnesium stearate are made into the tablet by die pressing and coated with the film by a coating machine. The dahurican patrinia tablet has the beneficial effects of improving the structure of a pill flan, substituting the film for sugarcoat and solving problems that a patient suffering diabetic can not take the tablet and the sugar-coat is affected with damp, gets mildew and goes bad easily. Compared with the prior medicine, the quality guarantee period of the medicine is prolonged by over 50 percent. The release time of the tablet is shortened to 10 minutes from 30 to 60 minutes. Therefore, the tablet is absorbed by people more easily and drug action is quicker.
The invention relates to a red wolfberry eyesight-improving nano eye cream for children and a preparation method thereof. The eye cream comprises the following raw material components: the health-care tea comprises lycium barbarum, zeaxanthin dipalmitate, lycium barbarum polysaccharide, lycium barbarum seed oil, a tea polyphenol extract, a honeysuckle extract, a chamomile extract, lecithin, trehalose, vitamin C, vitamin A, tocopherol, xanthan gum and distilled water. The eye cream is rich in natural plant active ingredients of the lycium ruthenicum, can be better absorbed by the nanotechnology, has the effects of improving eyesight and moistening dry eyes, is green and healthy, and does not contain artificial pigments. The problem of oxidation of free radical inflammatory cells around eyes is solved to the maximum extent, so that the effect of improving eyesight of children for improving the problem of eye vision loss is achieved. With the progress of social modernization, the incidence rate of myopia is increasing, and the myopia becomes one of the eye diseases with the highest incidence rate in the world. According to data display, about 500 more than ten thousand blind people, 600 more than ten thousand low-vision people and 1000 ten thousand children with oblique amblyopia exist in China. The average myopia rate of teenagers reaches 40%, and the myopia rate of college students is far more than 70%. Research shows that the myopia of teenagers tends to be low-age in China. The product uses pure natural and non-irritant active ingredients, and the liposome nanotechnology is utilized for entrapment delivery to achieve a better transdermal absorption effect, so that the effects of improving eyesight and relieving eye myopia are achieved.
Patients with obsessive-compulsive disorder who presents with aggressive obsessions (also known as taboo thoughts e.g. fear of being a pedophile) and mental rituals have shown to respond less well to treatment. Thus, there is room for further innovation. The primary objective of this pilot study is to investigate if an internet-based cognitive therapy (I-CT) is feasible and effective in reducing the frequency and distress of aggressive obsessions. The study will also investigate if I-CT is associated with any significant side effects. Another objective of this study is to get a power estimate of the treatment effects for a subsequent randomized controlled study (RCT). This will be done by using an open pilot study with repeated measurements.
Calcium Chloride Injection, USP, 10% is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues. 

Solutions should be warmed to body temperature. Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope. If injected into the ventricular cavity in cardiac resuscitation care must be taken to avoid injection into the myocardial tissue.
OBJECTIVES: The aim was to compare voice outcomes over time in patients treated with Imitation Model voice therapy and Verbal Instructions Model voice therapy.
METHODS: A prospective clinical trial was performed with 56 consecutive patients diagnosed with a primary or secondary functional voice disorder. Thirty-one patients were included for voice therapy following the Imitation Model and 25 patients for the Verbal Instructions Model. Assessments included a self-rated Voice Handicap Index, self-perceived hoarseness and vocal fatigue, perceptual voice evaluation by a Speech Language Pathologist, and maximum Voice Range Profiles. All assessments were completed before therapy, at end of therapy, at six-months posttherapy follow-up and 12-months posttherapy follow-up. For maximum Voice Range Profiles group differences were also compared for effects from end-of-treatment to follow-up assessments. Linear mixed models were used for analysis.
RESULTS: Comparison between treatment groups showed significantly larger long-term improvement from the baseline, for verbal instructions model as compared to imitation model for Voice Handicap Index total, and also the physical and emotional subscales, while there was no difference between groups for the functional subscale. Also, voice quality improved more after verbal instructions model, as compared to imitation model, at end of therapy. Results from self-rated hoarseness and vocal fatigue showed no difference between groups. There was no difference between treatment groups in the change of maximum Voice Range Profile from end-of-treatment to follow-up assessments.
CONCLUSIONS: The study showed that both Imitation Model voice therapy and Verbal Instructions Model voice therapy improved voice function. Compared to Imitation Model, the Verbal Instructions model showed larger long-term effect on physical and emotional aspects of voice function in everyday life. The two approaches for voice therapy might have different impacts on patients' learning.
The prevalence of obesity (defined as body mass index (BMI, kg/m2) ≥ 30) has significantly increased, affecting approximately 35% of adult females in the United States, according to CDC 2009-2010 statistics. Obesity has a significant impact on pregnancy, including increased need for cesarean section and post-operative wound complications. Infection rates have been reported to be between 10 and 30%. The advent in 1997 of negative pressure therapy (NPT), also known as vacuum assisted closure (VAC), has vastly changed wound care management. Briefly, VAC has been traditionally applied to a chronic wound to create negative or sub-atmospheric pressure, thus promoting wound healing by decreasing edema and increasing blood flow and formation of granulation tissue. Use of this therapy at the time of primary closure of a surgical incision (first trialed in 2006 and termed "Incisional VAC") has provided a promising approach to reducing post-operative wound infection. Incisional VAC has been explored primarily in the orthopedic and cardiothoracic fields, but very few studies have examined the use on abdominal incisions, and only one to date on cesarean section incisions.
The invention discloses lactobacillus reuteri as a canine source, a microbial inoculum and application thereof, and relates to the technical field of probiotics. The canine lactobacillus reuteri is separated and screened, and the strain has higher free radical scavenging capability and good antioxidant capability, is beneficial to anti-aging of animals and prolongs the service life of pets. The acid resistance is excellent, the high temperature resistance, the bile salt resistance and the gastrointestinal fluid resistance are good, and the water is moderately hydrophobic. Therefore, the strain has good intestinal tolerance and adhesiveness, is beneficial to the field planting in the intestinal canal, and can exert the probiotic function for a long time. Can effectively inhibit growth and proliferation of Escherichia coli, staphylococcus aureus and Salmonella, and can be used for preventing or treating diarrhea. The microbial inoculum provided by the invention has wide application prospect and can be used for preparing medicines, feeds and foods.
This is an open-label (the researchers and participants know the treatment the participant is receiving), multicenter (more than 1 study site), long-term safety and efficacy study of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD). Participants will enter the study either directly (direct-entry participants) or after completing the Double-Blind Induction Phase of ESKETINTRD3005 (transferred-entry participants). The study consists of 4 phases: Screening Phase (4 weeks), Open-Label Induction Phase (4 weeks), Open-Label Optimization/Maintenance phase (48 weeks), and Follow up Phase (4 weeks). Transferred entry non-responders in the ESKETINTRD3005 may enter study at the Open-Label Induction Phase and responders in the ESKETINTRD3005 may enter Optimization/Maintenance phase. In the Open-Label Induction Phase, participants will self-administer flexibly-dosed intranasal esketamine (participants who are less than (\<) 65 years old self-administer 56 mg or 84 mg dose, participants who are greater than or equal to (\>=) 65 years old self-administer 28 mg, 56 mg or 84 mg dose) twice weekly for 4 weeks. The starting dose for all participants \>= 65 years old will be 28 mg. In addition, each direct-entry participants will be assigned to receive 1 of 4 selected oral antidepressant medications (escitalopram or sertraline or duloxetine or venlafaxine extended release \[XR\]), initiated on Day 1 of the open-label induction phase and continued through the duration of the study. Transferred-entry participants will continue their same antidepressant from ESKETINTRD3005 through the duration of this study. Participants who are responders at the end of the Open-Label Induction phase and transferred-entry responder participants (from study ESKETINTRD3005) will enter the Optimization/Maintenance Phase where intranasal esketamine treatment sessions will be reduced from that in the induction phase (twice weekly) to weekly for the first 4 weeks of this phase, and then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Participants' safety and depressive symptoms will be assessed and monitored throughout the study.
Treatment with OTEZLA is associated with an increase in adverse reactions of depression. Before using OTEZLA in patients with a history of depression and/or suicidal thoughts or behavior prescribers should carefully weigh the risks and benefits of treatment with OTEZLA in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with OTEZLA if such events occur. 

Psoriatic arthritis: During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of subjects treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. During the clinical trials, 0.3% (4/1441) of subjects treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated subjects (0/495). Depression was reported as serious in 0.2% (3/1441) of subjects exposed to OTEZLA, compared to none in placebo-treated subjects (0/495). Instances of suicidal ideation and behavior have been observed in 0.2% (3/1441) of subjects while receiving OTEZLA, compared to none in placebo treated subjects (0/495). In the clinical trials, 2 subjects who received placebo committed suicide compared to none in OTEZLA-treated subjects.

Psoriasis: During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.3% (12/920) of subjects treated with OTEZLA reported depression compared to 0.4% (2/506) treated with placebo. During the clinical trials, 0.1% (1/1308) of subjects treated with OTEZLA discontinued treatment due to depression compared with none in placebo-treated subjects (0/506). Depression was reported as serious in 0.1% (1/1308) of subjects exposed to OTEZLA, compared to none in placebo-treated subjects (0/506). Instances of suicidal behavior have been observed in 0.1% (1/1308) of subjects while receiving OTEZLA, compared to 0.2% (1/506) in placebo-treated subjects. In the clinical trials, one subject treated with OTEZLA attempted suicide while one who received placebo committed suicide.

Behçet's disease: During the placebo-controlled period of the phase 3 study, 1% (1/104) of patients treated with OTEZLA reported depression/depressed mood compared to 1% (1/103) treated with placebo. None of these reports of depression was serious or led to study discontinuation. No instances of suicidal ideation or behavior were reported during the placebo-controlled period of the phase 3 study in patients treated with OTEZLA (0/104) or treated with placebo (0/103).
The invention provides a microorganism strain of the family trichomonadaceae, a medicament for preventing and/or treating obesity, diabetes, hyperlipidemia and other metabolic diseases and application thereof, and relates to the technical field of biological medicines. The invention relates to a novel genus-level novel species (Lachnospiraceae sp.) of a microorganism strain belonging to the family Lachnospiraceae, and the nucleotide sequence of 16S rDNA of the microorganism strain belonging to the family Lachnospiraceae is shown as SEQ ID No. 1. The present invention finds that the novel genus-level intestinal anaerobic microorganism strain Lachnospiraceae sp is useful for slowing, preventing and/or treating metabolic diseases. The discovery of the invention enriches the types of strains with the function of treating or preventing metabolic diseases, and has good application prospect.
Graves' ophthalmopathy (GO) is an organ-specific autoimmune disease closely related to the thyroid gland, typically manifested by proptosis, eyelid swelling, eye pain, and double vision. Mild GO may resolve with the control of hyperthyroidism, while moderate to severe GO can severely damage vision and require more aggressive treatment. Glucocorticoids are the first-line treatment for moderate to severe, active GO, and intravenous methylprednisolone is more effective than oral glucocorticoids. The 2021 clinical practice guidelines of the European Group on Graves' Orbitopathy (EUGOGO) recommend that the optimal dosage regimen for methylprednisolone is once a week for 12 weeks, with a cumulative dose of 4.5 grams. For the most severe cases, a higher cumulative dose of up to 8 grams can also be used as monotherapy.

Starting from the 1990s, the Endocrinology Department of Shanghai Changzheng Hospital began to admit patients with Graves' ophthalmopathy and initiated immunosuppressive pulse therapy, accumulating nearly 1000 cases of GO, making it the hospital with the most patients with Graves' ophthalmopathy in Shanghai and even nationwide. The monthly pulse therapy regimen has a high treatment response rate, a low relapse rate, and good safety. However, there are still a series of unresolved issues with glucocorticoid pulse therapy for Graves' ophthalmopathy. Firstly, the optimal cumulative dose of methylprednisolone has not been established. Secondly, the active course of Graves' ophthalmopathy varies greatly among individuals, with reports ranging from a few months to several years, and the pulse therapy has not yet been individualized. Thirdly, there is a significant difference in individual sensitivity to glucocorticoids; the fixed high-dose administration of methylprednisolone at 500mg per session lacks sufficient evidence. Calculating the single-dose administration based on body weight or surface area may be more reasonable.

The efficacy and safety of different dosage regimens of methylprednisolone pulse therapy for Graves' ophthalmopathy will be further explored. This study plans to include newly diagnosed, active, moderate to severe Graves' ophthalmopathy patients, divided into a high-dose group (methylprednisolone 500mg, D1-3, once every 4 weeks) and a low-dose group (methylprednisolone 1mg/kg, D1-3, once every 4 weeks), with a treatment duration of 24 weeks to compare the efficacy and safety of the two groups. Additionally, this study will extend the follow-up to 48 weeks to observe the recurrence rate after treatment in both groups, exploring the heterogeneity of the active course of Graves' ophthalmopathy.
PURPOSE:A remedy and preventive for thrombosis for inhibiting aggregation action of human blood platelet by arachidonic acid, containing docosahexaenoic acid, its salt, ester or amide derivative as an active ingredient. CONSTITUTION:A remedy and preventive for thrombosis containing decosahexaenoic acid (DHA for short), its pharmaceutically acceptable salt, its ester, or amide derivative as an active ingredient. DHA has 22C and six double bonds, and exists in a fish oil of rainbow traut. DHA is found to inhibit aggregation of human blood platelet and to be effective for remedying and preventing thrombosis. Sodium docosahexaenoate, methyl docosahexaenoate, etc. may be cited as a preferable concrete example of DHA.